Search clinical trials for: BI 425809 (Treatment T1)

Total 47 results

Boehringer Ingelheim

Completed

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Alzheimer Disease

Spain, United Kingdom, Italy, United States, Canada, Germany, Greece, Austria, Norway, France, Japan, Hungary, Poland, Finland
Boehringer Ingelheim

Completed

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Schizophrenia

Spain, Korea, Republic of, United Kingdom, Taiwan, United States, Austria, Italy, Germany, Poland, Japan, Canada
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems

Hepatic Insufficiency

Germany
Insud Pharma

Completed

Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)

Helminthiasis
Boehringer Ingelheim

Completed

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Schizophrenia

United States, United Kingdom, Australia, Canada, France, New Zealand
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems

Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Schizophrenia

Korea, Republic of, Canada, United States, Taiwan, United Kingdom, Chile, Serbia, Brazil, China, Colombia, Germany, Greece, Italy, Japan, Mexico, Norway, Poland, Sweden, Spain, Argentina, Croatia, France, Slovakia, Denmark, Malaysia, Czechia and more
Boehringer Ingelheim

Recruiting

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

Schizophrenia

United States, Taiwan, Argentina, Brazil, Serbia, Germany, China, Mexico, Korea, Republic of, Bulgaria, United Kingdom, Czechia, Denmark, Austria, Lithuania, Portugal, Belgium, Finland
Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects

Healthy Volunteers

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other

Healthy

Germany
University of Michigan
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

SafERteens M-Coach

Alcohol Drinking | Violence

United States
Boehringer Ingelheim

Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Hepatitis C, Chronic

United States, Australia, Belgium, Canada, France, Germany, Greece, Italy, New Zealand, Portugal, Spain, United Kingdom
Wissenschaftliches Institut Bethanien e.V

Completed

Validation of a New Automatic Bi-level Algorithm in the Treatment of Sleep-disordered Breathing

Obstructive Sleep Apnea

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

Healthy

United States
University of Michigan
National Heart, Lung, and Blood Institute (NHLBI); Michigan Technological University

Completed

Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children

Sleep Apnea Syndromes | Sleep Apnea, Obstructive | Disorders of Excessive Somnolence | Attention Deficit Disorder With Hyperactivity | Child Behavior Disorders

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects

Healthy

Germany
University of Alabama at Birmingham

Recruiting

Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA (TALC)

Hiv | Alcohol Problem

United States
Boehringer Ingelheim

Completed

A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood

Healthy

Germany
University of Alabama at Birmingham
Columbia University; Centre for Infectious Disease Research in Zambia

Recruiting

Common Elements Treatment Approach HIV Alcohol Reduction Trial in Zambia (CHARTZ)

Alcohol-Related Disorders | HIV/AIDS | Mental Illness

Zambia
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Asahi Kasei Pharma Corporation

Recruiting

Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Sangath

Completed

Alcohol Use Disorders- Mobile Based Brief Intervention Treatment (AMBIT): A Pilot RCT (AMBIT)

Hazardous Drinking

India
Boehringer Ingelheim

Completed

DDI Strong CYP3A4 Inducer

Healthy

Germany
National Taiwan University

Completed

Efficacy of Drug and Risk Behavior Counseling Intervention Among Injecting Drug Users at Opioid Substitution Treatment

Substance Use Disorders
University of California, San Francisco

Withdrawn

The Effect of Buccal Infiltration Administration of Clonidine on the Success Rate of Inferior Alveolar Nerve Block

Symptomatic Irreversible Pulpitis
Cairo University

Recruiting

Progressive Resisted Exercise Plus Aerobic Exercise on Osteoporotic Systemic Lupus Erythmatosus

Systemic Lupus Erythematosus

Egypt
Boehringer Ingelheim

Completed

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Healthy

Germany
Centre Hospitalier Universitaire de Nīmes

Completed

Low Energy Shockwave Therapy for Improving Erectile Dysfunction (Shock-ED)

Erectile Dysfunction

France
Tan Tock Seng Hospital
Melbourne Health; National University Hospital, Singapore; Samsung Medical Center and other collaborators

Recruiting

Early Oral Step-down Antibiotic Therapy for Uncomplicated Gram-negative Bacteraemia

Gram-negative Bacteraemia

Singapore
Northwestern University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Atypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial Meningioma

United States
Boehringer Ingelheim

Completed

The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)

Healthy

Germany
Boehringer Ingelheim

Completed

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

Healthy
University of Washington
National Cancer Institute (NCI)

Completed

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States

3

Subscribe